Moderna's COVID-19 vaccine won't be ready by US election: report
In this file photo taken on August 13, 2020 Biotechnology company Moderna protocol files for COVID-19 vaccinations are kept at the Research Centers of America in Hollywood, Florida. US biotech firm Moderna won't seek an emergency use authorization for its coronavirus vaccine before November 25, its CEO told the Financial Times on September 30.
AFP/CHANDAN KHANNA
Moderna's COVID-19 vaccine won't be ready by US election: report
(Agence France-Presse) - October 1, 2020 - 7:58am

WASHINGTON, United States — US biotech firm Moderna won't seek an emergency use authorization for its coronavirus vaccine before November 25, its CEO told the Financial Times on Wednesday.

The news deals a blow to President Donald Trump's hopes of having an injection ready before the election to give his campaign a much-needed boost.

Stephane Bancel told the newspaper: "November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA (Food and Drug Administration) — assuming that the safety data is good, i.e. a vaccine is deemed to be safe."

Trump, whose approval has taken a hit over his handling of the COVID-19 crisis, has frequently hinted a vaccine could be ready before the November 3 vote.

This has raised concern among experts that his administration may attempt to interfere with the regulatory process for political reasons.

The Republican repeated his claim on Tuesday night, during a debate with his Democratic rival, former vice president Joe Biden.

"It's a possibility that we'll have the answer before November 1," he said.

Moderna's vaccine is one of 11 experimental vaccines in final stage trials.

Another is being developed by Pfizer, whose CEO Albert Bourla has taken the position that his company may have a clear answer about whether their shot works by October.

Most experts are skeptical of the claim, believing that the ongoing trials will not have sufficient statistical data to prove the drug's safety and effectiveness by that time.

Speaking to the Washington Post on Tuesday, Bourla denied he was attempting to curry favor with the president by making his October claim.

"For me, the election day is an artificial day. The end of October is an artificial day. This is how we operate. If we can bring it earlier, we will," he said.

2020 US PRESIDENTIAL RACE COVID-19 VACCINE MODERNA NOVEL CORONAVIRUS
As It Happens
LATEST UPDATE: October 27, 2020 - 9:45am

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

October 27, 2020 - 9:45am

Brazil is a top testing ground for vaccines against COVID-19, but its plans for vaccinating its own population have been plunged into chaos by a political war waged by President Jair Bolsonaro.

Hit hard by the new coronavirus, Brazil has been tapped to help test several of the leading vaccine candidates, giving it a potential edge in the race to secure access to an eventual shot.

That could be a welcome silver lining for the country of 212 million people, which has the second-highest COVID-19 death toll in the world, at more than 157,000.

But one promising test vaccine, developed by Chinese pharmaceutical firm Sinovac Biotech, has triggered the ire of the far-right president, who last week canceled his health minister's plan to buy 46 million doses. 

The vaccine's most visible proponent in Brazil is the governor of the large and wealthy state of Sao Paulo, Joao Doria, who also happens to be one of Bolsonaro's top opponents. — AFP

October 21, 2020 - 12:38pm

Brazil's health minister says the country would add the Chinese-made CoronaVac vaccine against COVID-19 to its national immunization program, despite a political and diplomatic row over whether to use it.

Health Minister Eduardo Pazuello says the federal government had reached a deal with Sao Paulo state, which is helping test and produce the vaccine, to buy 46 million doses to be administered starting in January.

"This vaccine will be Brazil's vaccine," in addition to another developed by Oxford University and pharmaceutical firm AstraZeneca, Pazuello says in a video meeting of the South American country's 27 governors. — AFP

October 7, 2020 - 3:41pm

The US Food and Drug Administration made public its guidance for issuing emergency approval for a COVID-19 vaccine on Tuesday, making it clear it wants to see follow-up two months after trial volunteers have their second dose.

It is therefore unlikely for President Donald Trump's administration to have a vaccine on the market before the November 3 election, something the president frequently says is on the cards.

"Data from Phase 3 studies should include a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adequate information to assess a vaccine's benefit-risk profile," the document said. — AFP

October 7, 2020 - 7:33am

The US Food and Drug Administration made public its guidance for issuing emergency approval for a COVID-19 vaccine on Tuesday, making it clear it wants to see follow-up two months after trial volunteers have their second dose.

It is therefore unlikely for US President Donald Trump's administration to have a vaccine on the market before the November 3 election, something the president frequently says is on the cards.

"Data from Phase 3 studies should include a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adequate information to assess a vaccine's benefit-risk profile," the document said.

The two companies that are furthest along in their vaccine trials, Moderna and Pfizer, both began their final stages at the end of July, and both require two separate injections 28 days apart. — AFP

September 30, 2020 - 8:10am

The World Bank says it has asked its board of directors to approve $12 billion to help poor countries purchase and distribute eventual vaccines against COVID-19.

The bank has already implemented emergency response programs in 111 countries and the extra money, if approved, would be aimed at low- and middle-income countries.

"An effective and safe COVID-19 vaccine is the most promising path forward for the world to reopen safely," a World Bank spokesman says. — AFP

Philstar
  • Latest
  • Trending
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with